ALX Oncology Holdings Inc. (ALXO)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.31−$0.0450 (−3.32%) on the dayAs of the close; data may be delayed.
ALXO price, last 12 months
Key stats
- Previous close
- $1.36
- Open
- $1.34
- Day range
- $1.29 – $1.37
- 52-week range
- $1.05 – $2.66
- Volume
- 1.2M
- Avg volume (20 days)
- 1M
- Market cap
- $181.1M
Performance
1W−22.9%
1M−33.8%
3M−35.8%
6M−35.8%
YTD+15.9%
1Y−15.5%
vs S&P 500, 1Y−32.3 pts
Technicals and fundamentals
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $181.1M